|Last Price$7.31||Day Change (%)-5.31%|
|Open Price$7.74||Day Change ($)-0.41|
|Day Range7.15–7.94||52-Week Range3.05–13.26|
As of Wed 01/28/2015 04:53 PM EST | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Research and Markets: Hypertension - Pipeline Review, H2 2014
Cytokinetics faces challenging odds.